NewGenIvf Enterprise Value Over E B I T D A from 2010 to 2026
| NIVF Stock | 0.60 0.03 4.87% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 1.8 K | Current Value 1 K | Quarterly Volatility 370.87188569 |
Check NewGenIvf Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewGenIvf Group's main balance sheet or income statement drivers, such as Interest Income of 8.4 K, Depreciation And Amortization of 216.5 K or Interest Expense of 940.2 K, as well as many indicators such as Price To Sales Ratio of 9.27, Dividend Yield of 0.0 or Days Sales Outstanding of 80.98. NewGenIvf financial statements analysis is a perfect complement when working with NewGenIvf Group Valuation or Volatility modules.
NewGenIvf | Enterprise Value Over E B I T D A | Build AI portfolio with NewGenIvf Stock |
Latest NewGenIvf Group's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of NewGenIvf Group Limited over the last few years. It is NewGenIvf Group's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewGenIvf Group's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
NewGenIvf Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 1,011 | |
| Geometric Mean | 964.49 | |
| Coefficient Of Variation | 36.69 | |
| Mean Deviation | 261.13 | |
| Median | 851.31 | |
| Standard Deviation | 370.87 | |
| Sample Variance | 137,546 | |
| Range | 1.3K | |
| R-Value | 0.57 | |
| Mean Square Error | 98,306 | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | 42.19 | |
| Total Sum of Squares | 2.2M |
NewGenIvf Enterprise Value Over E B I T D A History
About NewGenIvf Group Financial Statements
NewGenIvf Group stakeholders use historical fundamental indicators, such as NewGenIvf Group's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although NewGenIvf Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in NewGenIvf Group's assets and liabilities are reflected in the revenues and expenses on NewGenIvf Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NewGenIvf Group Limited. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 1.8 K | 1 K |
Currently Active Assets on Macroaxis
When determining whether NewGenIvf Group is a strong investment it is important to analyze NewGenIvf Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NewGenIvf Group's future performance. For an informed investment choice regarding NewGenIvf Stock, refer to the following important reports:Check out the analysis of NewGenIvf Group Correlation against competitors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewGenIvf Group. If investors know NewGenIvf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewGenIvf Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.4 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
The market value of NewGenIvf Group is measured differently than its book value, which is the value of NewGenIvf that is recorded on the company's balance sheet. Investors also form their own opinion of NewGenIvf Group's value that differs from its market value or its book value, called intrinsic value, which is NewGenIvf Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewGenIvf Group's market value can be influenced by many factors that don't directly affect NewGenIvf Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewGenIvf Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewGenIvf Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewGenIvf Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.